Sente, Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Sente, Inc. - overview
Established
2007
Location
Carlsbad, NM-New Mexico, US
Primary Industry
Consumer Products
About
Sente, Inc. is a skincare company specializing in medical-grade products that enhance skin health and appearance through innovative formulations targeted at dermatologists and skincare professionals. Founded in 2007 and based in Encinitas, US, Sente, Inc. is dedicated to developing advanced skincare solutions.
In April 2026, Sente, Inc. raised an undisclosed amount of venture funding. The CEO of Sente is Laurent Combredet, while the company was founded by Kleanthis Xanthopoulos. Sente specializes in medical-grade skincare products designed to enhance skin health and appearance through innovative formulations.
The company's core offerings include a range of serums and creams, such as their Hydrate + Serum, which utilizes a patented molecule known as Heparan Sulfate Analog (HSA) to address common skin concerns like redness, hyperpigmentation, and fine lines. These products are engineered to boost the skin's natural immune response to inflammation, promote dermal repair, and achieve an even skin tone. Sente's customer base primarily consists of dermatologists, skincare professionals, and end-users seeking effective solutions for skin issues, focusing on markets in North America and select international regions. The revenue structure of Sente is driven by direct sales to consumers and partnerships with skincare professionals and retailers.
Customers can purchase individual products, such as the flagship Hydrate + Serum priced at USD 89, or bundles that may offer combined solutions for various skin concerns. The company's sales model emphasizes direct-to-consumer transactions, allowing users to access personalized skincare regimens through quizzes that recommend specific products. Additionally, promotions such as discounts for first-time purchasers further support customer engagement and sales growth. Sente's focus on high-quality, clinically backed skincare products positions it competitively in the medical-grade skincare market.
The company will use the April 2026 funding to accelerate growth and expand the reach of its patented technologies that support its clinically proven skincare products.
Current Investors
PharmaBio Investments
Primary Industry
Consumer Products
Sub Industries
Beauty & Hygiene, Aesthetic Medicine
Website
sentelabs.com
Verticals
Manufacturing
Company Stage
Series C
Total Amount Raised
Subscriber access only
Sente, Inc. - deals
| Deals Type | Deal Status | Target (s) | Deal Date | Investor(s) | Seller(s) | Deal size (Mn) | Enterprise value (Mn) | Post-money valuation (Mn) | EBITDA multiple (x) | Revenue multiple (x) | Lead partner (s) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Unspecified Round | Completed | Sente, Inc. | - | ||||||||
| Series C | Completed | Sente, Inc. | - | ||||||||
| Series B | Completed | Sente, Inc. | - | ||||||||
| Series B | Completed | Sente, Inc. | - | ||||||||
| Venture Debt | Completed | Sente, Inc. | - |
Displaying 1 - 5 of 6
Sente, Inc. - employee data
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.